Xaliproden

Xaliproden

Systematic (IUPAC) name
1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
Identifiers
CAS Number	135354-02-8 Y
ATC code	N07XX03 (WHO)
PubChem	CID: 128919
ChemSpider	114237 N
UNII	V8QL94KNQO Y
KEGG	D06327 Y
Chemical data
Formula	C24H22F3N
Molecular mass	381.433 g/mol
SMILES FC(F)(F)c4cccc(/C3=C/CN(CCc2cc1ccccc1cc2)CC3)c4
InChI InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2 N Key:WJJYZXPHLSLMGE-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Xaliproden (codenamed SR57746) is a drug which acts as a 5HT_1A agonist. It has neurotrophic and neuroprotective effects in vitro, and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

Development of xaliproden for these two indications was discontinued in 2007 following analysis of Phase III data. While the drug did show an effect on hippocampal volume (suggesting perhaps a slowing of cell loss), there was insufficient evidence for efficacy in counteracting Alzheimer's related cognitive decline. Similarly while there were some indicators of efficacy in ALS, including a small but clinically noteworthy effect on some functional parameters, the overall benefit did not reach statistical significance when results across several Phase III trials were averaged. Xaliproden remains under investigation for treatment of chemotherapy-induced peripheral neuropathy.